GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition
First Vaccine M&A Deal For Departing Barron
GSK has spotted an opportunity to challenge Pfizer’s blockbuster Prevnar franchise, but the potential of Affinivax’s platform has yet to be proven.
You may also be interested in...
The vaccine, V116, targets eight unique serotypes, and it is particularly geared toward preventing pneumococcal disease in adults, especially the elderly, according to Merck.
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
The biotech’s share price jumps more than two-thirds as analysts hail top-line Phase I/II data as better than expected. Vaxcyte hopes to hold Phase III planning discussions with the FDA in 2023.